Equity Markets
Editorial articles and market analysis covering Equity Markets on FinancialMarkets.com.
Latest articles
- SpaceX Says Any Tesla Combination Would Need Its Controlling Shareholder's Approval
- SpaceX Is Seeking Space on 80,000 U.S. Cell Sites, Bloomberg Reports. Tower Stocks Jumped After Hours and Carriers Fell
- Moderna's Vaccine Cleared Every Published Bar. The Stock Still Lost $17 Billion
- Moderna Lost About a Fifth of Its Value Before the Official Data Were Out. Most of Its 733% Gain Came After a Result Without Numbers
- Elon Musk Has Put About $1 Billion Into Skydance, Semafor Reports. The Stock Barely Moved
- Chipmakers Fell 6%. Power and Turbine Stocks Fell More
- The FDA Will Look Again at Biohaven's Ataxia Drug. The Evidence Problem Has Not Gone Away
- Meta Raised Its Spending Floor and Lam Research Beat. Chip and AI Stocks Fell Anyway, From Seoul to New York Futures
- Meta Says It Will Sell Its New Non-Voting Stock. The Same Filing Gives Zuckerberg a Path to Sell Shares Without Losing Control
- Musk Says Tesla and SpaceX Have Formed Merger Committees and That He Cannot Sit on Them. Together the Companies Are Worth Nearly $3.7 Trillion
- A Judge Ordered Meta to Pay $25 Billion, More Than Seven Times the Cap the Company Proposed. The Stock Dipped Less Than 0.5% and Recovered
- Getty Images' Founding Family and Koch Would End Up Owning All of It After a Prepackaged Bankruptcy. Common Shareholders Are Set to Get Nothing
- Super Micro's Revenue Estimate Came In 27% Above Its Own Guidance. The Gross Profit Behind It Beat by About 46%
- Musk Backs Combining Tesla and SpaceX, Then Lists the Obstacles: No Terms, No Seat at the Table and a High Tesla Vote Bar
- Health-Care Stocks Ran to the Edge of a Record and Small Caps Rose 1.7% in the Same Session. Both Can't Be a Flight to Safety
- Labcorp Is Paying About 1.3 Times the Revenue It Expects From Myriad's Prenatal Unit. For Myriad, the Check Is Worth Half the Company
- Lionsgate Added About Half a Billion Dollars of Market Value Within Minutes of a Takeover Report. Nobody Has Named a Price
- Salesforce Is Paying $47.50 a Share for Braze, 58% Over Monday's Close. Shareholders Who Bought the 2021 IPO Are Still Underwater
- Jio's Anchor Investors Took About 27% of Its IPO at the Top Price. A Public Tranche Nearly Three Times Larger Opens Wednesday
- Amazon Is Funding a 960-Megawatt Reactor Study in Indiana. X-energy Gave Back About Three-Quarters of Its Opening Jump
- Seoul Undid Wall Street's AI Rebound Within Hours. A Data-Center Listing Priced at the Top of Its Range Fell as Much as 32% on Day One
- Chip Stocks Rebounded From Their Worst Week Since April 2025 as Bond Yields Rose. CoreWeave Did Not Join In
- EyePoint's Eye Drug Missed in a Second Wet AMD Trial. The Company Now Trades at About a Third of Its Cash
- Silgan Gets $2.3 Billion and Keeps 60% in Its Trivium Deal. The New Venture's Debt Stays on Silgan's Books
- Disc Medicine's Final Trial Targets the FDA's Main Objection. Its Stock Is Still Below Its 52-Week High
- Silence Therapeutics Sells for $20 a Share. Whether That Is a 130% Premium or a 30% One Depends on the Starting Date
- A Regulator Found Debanking Policies at All Nine of Its Largest Banks. It Has Not Said What It Will Do
- SpaceX Is Worth $2.5 Trillion and Now Sits in the Middle of a U.S.-Ukraine Dispute
- Accenture's China Review Could End in a Partial Exit, Not a Clean Sale
- Dai-ichi Life Already Owns a Fifth of Challenger. Its A$11.80 Bid for the Rest Is Non-Binding